/R E P E A T — Biosign Technologies Appoints Dr. Scott Jenkins as CEO/

-Healthcare IT executive to lead international health monitoring
company-

TORONTO, June 22, 2011 /PRNewswire/ – Biosign Technologies Inc. (TSXV: BIO), a
company focused on non-invasive, cloud based-health monitoring, is
pleased to announce that Dr. Scott Jenkins has been appointed as Chief
Executive Officer (CEO) of the company, effective July 5, 2011. Dr.
Jenkins will assume this role from Biosign’s acting CEO and Founder,
Dr. Radu Leca.

Dr. Jenkins has extensive experience in healthcare, life sciences,
medical devices and information technology business development and
global sales.  Most recently, Dr. Jenkins was the Vice President of
Worldwide Solution Sales at DELL Healthcare and Life Sciences, where he
was directly responsible for managing over 500 channel solution
partners. Previously, Dr. Jenkins has held various senior positions
with, Applied Biosystems, IBM Healthcare & Life Sciences, and Apple.

“The Board was searching for an individual to take Biosign to the next
level on a global scale,” stated Dr. David Silver, Biosign’s Chairman.
“We are thrilled to have attracted an individual like Scott who can
combine deep scientific understanding, healthcare technology industry
solutions and global sales – and has a proven track record of doing so
for other global organizations.”

“After using the UFIT system for several months and fully understanding
its unique capabilities and broader potential for personalized
medicine, I realized that my background and experience are perfectly
suited to help Biosign grow and realize its full potential,” stated Dr.
Jenkins.

In connection with Dr. Jenkins’ appointment, Biosign will be
centralizing the sales and marketing operations of the company in the
San Francisco bay area, while keeping the science and technology
development activities in Thornhill, Ontario, under the direction of
Dr. Leca, President.

Dr. Jenkins has lectured and presented papers at numerous worldwide
conferences, including the Milken Institute, Best Practices in
Personalized Medicine, The Galan Institute and Personalized Medicine
World. Dr. Jenkins earned a B.S. Organic Chemistry, Minnesota State
University and his Ph.D. in Synthetic Organic Chemistry, University of
Minnesota.

About Biosign Technologies Inc

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign’s actual results could differ materially from those
anticipated. Forward- looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information, please refer to risk factors detailed in,
as well as other information contained in, Biosign’s filings with
Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.